Although infrequent, RET fusions appear to be associated with a high risk of brain metastases, which was demonstrated by the finding that the cumulative incidence of CNS lesions in RET-positive NSCLC patients is higher than that in ROS1-positive patients [32]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.